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R E V I E W
Abstract: Poor adherence with antihypertensive therapies is a major factor in the low rates
of blood pressure control among people with hypertension. Patient adherence is influenced
by a large number of interacting factors but their exact impact is not well understood, partly
because it is difficult to measure adherence. Longitudinal prescription data can be used as a
measure of drug supply and are particularly useful to identify interruptions and changes of
treatment. Obtaining a medicine does not ensure its use; however, it has been established that
continuous collection of prescription medications is a useful marker of adherence. We found
20 studies published in the last 10 years that used large prescription databases to investigate
adherence with antihypertensive therapies. These were assessed in terms of patient selection,
the definition of the adherence outcome(s), and statistical modeling. There was large variation
between studies, limiting their comparability. Particular methodological problems included:
the failure to identify an inception cohort, which ensures baseline comparability, in four studies;
the exclusion of patients who could not be followed up, which results in a selection bias, in
17 studies; failure to validate outcome definitions; and failure to model the discrete-time
structure of the data in all the studies we examined. Although the data give repeated
measurements on patients, none of the studies attempted to model patient-level variability.
Studies of such observational data have inherent limitations, but their potential has not been
fully realized in the modeling of adherence with antihypertensive drugs. Many of the studies
we reviewed found high rates of nonadherence to antihypertensive therapies despite differences
in populations and methods used. Adherence rates from one database ranged from 34% to
78% at 1 year. Some studies found women had better adherence than men, while others found
the reverse. Novel approaches to analyzing data from such databases are required to use the
information available appropriately and avoid the problems of bias.
Keywords: patient adherence, antihypertensives, prescription databases
Introduction
Recent guidelines emphasize the importance of blood pressure control to reduce
cardiovascular morbidity and mortality (Guidelines Committee 2003). However,
control of blood pressure among hypertensives remains low – at approximately 13%
in the UK (Health Survey for England 2002). One of the reasons for this is poor
adherence with therapeutic regimens; Flack et al (1996) have previously documented
the relationship between poor adherence and lack of blood pressure control. DiMatteo
et al (2002) found a difference in blood pressure of 30% (95% confidence interval
12%, 46%) between hypertensive patients with high and low adherence.
The WHO definition of adherence is “the extent to which a person’s behaviour –
taking medication, following a diet, and/or executing lifestyle changes, corresponds
with agreed recommendations from a health care provider” (WHO 2003, p 3).
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A variety of terms are used for outcome measures in
quantitative studies of adherence; here we use the WHO
definition for adherence and terms used in individual studies
according to their own definitions.
While collection of a prescription does not ensure its
use, assessment of adherence with antihypertensive
regimens using prescription data has been validated by
comparison with electronic monitoring (MEMS) (Choo et
al 1999) and other measures of compliance and drug
presence or effect (Steiner and Prochazka 1997). Steiner
and Prochazka, in their assessment of refill compliance using
pharmacy claims data concluded that in large populations,
this type of data “can provide otherwise unobtainable
information about the pattern and timing of drug exposure,
and the determinants and consequences of adherence”
(Steiner and Prochazka 1997, p 105). They also found that
the acquisition of drug oversupplies was rare.
Prescription claims data are especially useful for
identification of nonadherence in the sense of dis-
continuation or changes in treatment. For adequate
determination of drug exposure patterns, it is necessary that
all prescriptions received by the patient during the
observation period are recorded in the database; that is,
patients do not collect prescriptions from some other source,
and the recording process is reliable.
Methods of assessment of adherence using prescription
refill data tend to be nonsystematic owing to use of different
definitions, and results are often not directly comparable.
The aim of this study is to examine the approaches to
investigating adherence with antihypertensive medications
using prescription databases.
Search criteria for inclusion
We made a comprehensive search for articles published in
the last 10 years (1995–2004) that used prescription claims
data to estimate adherence with antihypertensive therapies.
This included searches of PubMed, CINAHL, and individual
journals. The criteria for selection were the combination of
terms for adherence with a term indicating hypertension and
the term “prescription”. Relevant references were identified
from the bibliographies of selected articles.
We assessed articles in terms of information available
in the database, selection of patients and therapies –
particularly the validity of patient exclusions – definition
of the outcome measures used to assess adherence, and
statistical methods used. We compared the methods and
results between certain studies included in the review.
Based on the selection criteria described above, we found
20 relevant articles published between 1995 and 2004 that
examined adherence to antihypertensive therapies. All were
based on European or North American prescription
databases that allowed the construction of longitudinal
patient prescription histories. The majority of these studies
were based on US populations, where databases included
Medicaid and Medicare claims (Monane et al 1997; Rizzo
and Simons 1997), the US Department of Defense United
Services Personnel Drug Program (USPDP) (Okano et al
1997), Veterans’ Health Administration (VHA) databases
(Ren et al 2002; Wang et el 2002), and pharmacy benefits
managers (PBM) databases (Bloom 1998; Benson et al 2000;
Dezii 2000; Conlin et al 2001; Wogen et al 2003; Taylor
and Shoheiber 2003). The Canadian studies were based on
the Saskatchewan Health database (Caro, Salas, et al 1999;
Caro, Speckman, et al 1999; Bourgalt et al 2001; Marentette
et al 2002). The European studies included a UK study based
on the Mediplus automated primary care database (Jones et
al 1995), an Italian prescription database for the Local Health
Unit in Ravenna (Degli Esposti E et al 2002; Degli Esposti
L et al 2002; Degli Esposti et al 2004), and the Mediplus
data of IMS Health, an insurance system covering patients
in France, Germany, and the UK (Hasford et al 2002).
Some of the prescription databases were specific to
populations with characteristics known to influence
adherence; for instance, insurance coverage, where patients
paying for their treatment may be more likely to adhere to
therapy. Therefore, it may not be appropriate to extrapolate
the conclusions of these studies to populations that do not
share these traits.
Table 1 summarizes the information available from each
study. Some databases included information on diagnoses
or could be linked by patient to diagnosis codes (which might
be available only in the event of a hospital discharge). Many
of the databases did not include information on diagnoses.
All databases included a unique patient identifier,
demographic information (minimally age and sex of the
patient), and information on all prescriptions received,
including date of prescription and type and quantity of the
drug received. None included information on what was
actually prescribed as opposed to what was claimed. Two
studies included patient questionnaires or interviews.
Patient selection criteria for
individual studies
Table 1 gives the characteristics of the study populations
considered in each study identified as described above.
Therapeutics and Clinical Risk Management 2005:1(2) 95
Adherence with antihypertensive drugs
Table 1 Characteristics of study populations
Nr of Follow- Antihypertensive Observation Other
Reference subjects up Diagnosis Age (y) drugs New time selection
Jones et al 10 222 6 mo ICD-9 401-405 > 40 ACE, BB, CCB, 4 mo that AHT Visits for 6-mo All new courses
(1995), UK diuretic observation AHT
Mediplus period
Monane et al 8643 1 y Hospital 65–99, Any AHT ≥ 1-mo 12 mo any AHT; Active use; at Hospital, nursing
(1997), New discharge mean 75.6 supply new only least 1 claim home etc patients
Jersey Medicaid only (SD 8.1) each 4 mo excluded
Medicare
Rizzo and Simons 7211 1 y ICD-9 401, Mean 59.4 ACE, BB, CCB, Not identified Continuous Nursing home
(1997) 401.1, 401.9 (SD 13.9) diuretic eligibility excluded random
Pennsylvania Monotherapy ≥ 1-mo sample selected
Medicaid supply
Okano et al 771 1 y No 20–49 ACE, CCB 6 mo selected Continuous 771/5947 enrolled
(1997), US Dept AHT; new only enrolment claims continuously
Defense at start and end
USPDP
Bloom (1998) 21 723 1 y No 35–71, ACE, BB, CCB, 12 mo any AHT; Not stated; Exclude nitrates,
Merck-Medco mean 56 thiazide,  AT2 new only dropouts antiarrhythmics,
managed care monotherapy considered to digoxin, warfarin,
have stopped? loop diuretics, and
migraine medicines
Caro, Salas, et al 74 181 5 y unless ICD-9 401, > 40, ACE, BB, CCB, 10 mo any AHT; Patients Exclude other
(1999) censored 401.1, 401.9 median 65 diuretic, combination new vs observed CVD, hepatic and
Saskatchewan other (All 56 AHTs established minimum 1 y, renal disease, and
Health in Saskatchewan 5410 exclusions pregnant women
formulary)
Caro, Speckman, 22 918 5 y unless ICD-9 401, > 40, ACE, BB, CCB, 10 mo any AHT; Censoring after Exclude other
et al (1999) censored 401.1, 401.9 median 63 diuretic new only 6-mo CVD, hepatic and
Saskatchewan monotherapy observation renal disease, and
Health pregnant women
Benson et al 7490 1 y No > 30 Amlodipine, atenolol, 90 days any AHT; Continuous Discontinue in
(2000) HCTZ/triamterene, new only eligibility first year; min 30
US HMO lisinopril, losartan, days therapy;
nifedipine, quinapril max 1200 per
drug
Dezii (2000) 3942 1 y No Not given Lisinopril or 6 mo any AHT; Continuous None
US PBM enalapril + HCTZ new only eligibility; some
Single tablet or claim at 1 y
2 separate tablets
Bourgalt et al 19 501 5 y unless Hospital 40–79, ACE, BB, CCB 12 mo any AHT Included Exclude CVD
(2001) censored discharge mean 60 monotherapy or including (ICD-9 402, 404,
Saskatchewan diagnosis only combination diuretics, 410–416, 420–429,
Health α-blockers, etc; 745.4–746.9) and
new only anticoagulants,
loop diuretics,
cardiac thyroid
and migraine
medicines
Conlin et al 15 175 4 y, same No 35–71, ACE, BB, CCB, 12 mo any AHT; Continuous Exclude nitrates,
(2001) cohort as mean 56 diuretic, new only eligibility, 6548 antiarrhythmics,
Merck-Medco Bloom AT2 monotherapy excluded from digoxin, warfarin,
managed care Bloom cohort loop diuretics, and
migraine medicines
continued overleaf
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Diagnostic data
Where diagnosis data were available, patients were included
in the study cohort based on this and prescription of selected
drugs. Diagnoses allowed varied between studies: in three
studies patients with the International Classification of
Diseases – 9th Revision (ICD-9) codes 401, 401.1, and
401.9, referring to essential hypertension and benign and
unspecified hypertension, were included (Rizzo and Simons
1997; Caro, Salas, et al 1999; Caro, Speckman, et al 1999),
while elsewhere patients with ICD-9 codes 401–405 were
chosen (Jones et al 1995; Marentette et al 2002), or it was
merely stated that patients had a diagnosis of hypertension
(Hasford et al 2002; Wang et al 2002).
Where diagnosis data were not available, patients were
selected on the basis of prescription of selected drugs, with
possible exclusions of patients based on other prescriptions.
The chosen antihypertensive drugs varied according to the
study. They included a selection from angiotensin-
converting enzyme (ACE) inhibitors, β-blockers, calcium
channel blockers, diuretics, and angiotensin-II antagonists,
Table 1 continued
Nr of Follow- Antihypertensive Observation Other
Reference subjects up Diagnosis Age (y) drugs New time selection
Ren et al (2002) 1292 2 y Not stated Mean 65.2 Any AHT Not identified Observed 2 y None
Boston Veterans’ (59% (SD 10.3) complete
Health response)
Degli Esposti E 7312 3 y No (hospital > 20 ACE (C09A), 12 mo any AHT; Leave/die Exclude if < 7 days
et al (2002) discharge only) BB (C07), new only excluded 478 treatment
Ravenna LHU CCB (C08),
diuretic (C03),
AT2 (C09C);
monotherapy
Marentette et al 46 458 5 y ICD-9 401-405 1–95, ACE, BB, CCB, AT2, 12 mo any AHT; 4571 (9%) Exclude patients
(2002) mean 61 diuretic; initial class new only patients receiving
Saskatchewan only; diuretic + AHT excluded as not α-blockers,
Health classified with other observed entire α-agonists, and
AHT period vasodilators
Mixed classes ≥ 1 class
Wang et al 496 1 y HT in previous > 40 Any AHT 180 days any Continuous Random sample
(2002), US HMO (50% year AHT; new only enrolment eligible patients
and Veterans’ response) sent questionnaire
Health
Hasford et al 2416 1 y New HT Mean 61 ACE, BB, CCB, New -exclude if Lost to Patients matched
(2002), IMS (SD 12.7) diuretic, AT2 HT diagnosis follow-up to irbesartan
Health Mediplus monotherapy previous year classed group
discontinued
Degli Esposti L 16 783 1 y No > 20, ACE (C09A), 12 mo any AHT; Leave/die None
et al (2002) mean 56.1 BB (C07), new only excluded (660)
Ravenna LHU (SD 18.3) CCB (C08),
diuretic (C03),
AT2 (C09C);
monotherapy
Wogen et al 142 945 1 y No Mean 63.1 Valsartan, 12 mo that class; Continuous None
(2003) (SD 14.0) amlodipine, new only eligibility
US PBM lisinopril
Taylor and 5732 1 y Yes 18–64 Amlodipine/ Not identified Continuous None
Shoheiber benazepril eligibility
(2003) or ACE + CCB
US PBM
Degli Esposti 14 062 1 y No > 20 ACE, BB, CCB, 12 mo any AHT; Leave/die None
et al (2004) diuretic, new only excluded (817)
Ravenna LHU AT2 monotherapy
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BB, β-blocker; CCB, calcium channel blocker; AT2, angiotensin-II antagonist; AHT, antihypertensive;
HCTZ, hydrochlorothiazide; ICD, International Classification of Diseases; CVD, cardiovascular disease; HT, hypertension; min, minimum; max, maximum; mo, month; y, year.
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some studies choosing particular drugs and others including
all drugs in each class.
In some instances patients with diagnoses indicating
cardiovascular and other comorbidities were excluded (Caro,
Salas, et al 1999; Caro, Speckman, et al 1999; Bourgalt et
al 2001) and in others this information was used to construct
covariates to be included in the predictive models for
adherence (Rizzo and Simons 1997; Degli Esposti E et al
2002; Degli Esposti L et al 2002; Degli Esposti et al 2004).
Similarly, the use of other drugs that could indicate certain
conditions such as angina and heart failure was used as a
basis for exclusion from the cohort (Bloom 1998; Bourgalt
et al 2001; Conlin et al 2001) or included as covariates (Degli
Esposti E et al 2002; Degli Esposti L et al 2002; Wogen et
al 2003; Degli Esposti et al 2004).
Monotherapy and combinations
Eight studies included only patients initiating anti-
hypertensive monotherapy. In the other studies patients
could be receiving prescriptions for single therapies or
combinations. In some studies combinations of anti-
hypertensives were treated as a separate drug class (Bourgalt
et al 2001; Marentette et al 2002), while in others the
prescription of other antihypertensives was controlled for
by including appropriate covariates in the model for
adherence (Rizzo and Simons 1997; Wogen et al 2003). Two
studies compared adherence to combinations in single-tablet
or separate-tablet forms (Dezii 2000; Taylor and Shoheiber
2003). Some studies appear to have ignored or not specified
how they handled combinations of antihypertensive
treatments in their analyses.
New users of antihypertensives
Most studies identified patients who were new users of
antihypertensive drugs; three did not (Rizzo and Simons
1997; Ren et al 2002; Taylor and Shoheiber 2003).
Identification of new patients allows baseline and subsequent
comparability: duration of therapy is known to have a major
influence on adherence, with those on therapy longer being
less likely to discontinue (Sackett 1976). Based on the
known reduction of the risk of discontinuation as duration
of therapy increases, most studies excluded established users
of antihypertensives. These patients’ total time on therapy
is unknown and therefore the effect of therapeutic duration
on the risk of stopping therapy cannot be assessed. New
users were determined in various ways, from diagnosis date
(one study; Hasford et al 2002) or by evidence of a period
without therapy previous to the inception date. The length
of this period ranged from 3 to 12 months; however, there
was usually no attempt to justify this choice. A study based
on the UK General Practice Research Database (UKGPRD)
concluded that a 4-month period without prescriptions was
not sufficiently long to identify new users of antihypertensive
drugs and that a 12-month period would be more appropriate
(Suarez et al 2000). This finding is not necessarily applicable
to other databases, but it is possible that the studies choosing
relatively short run-in periods may include a substantial
number of patients who are not new to antihypertensive
therapy. In the studies reviewed, patients were variously
considered new to therapy if they had received no
antihypertensive prescriptions, no prescriptions for drugs
in the same class, or no prescriptions of the particular drug
during this period. Patients who have previously been
prescribed a different antihypertensive are not new to
therapy; they have been prescribed antihypertensives for an
unknown duration. Changing to a new type of therapy does
not make them new users, but three studies included them
as such (Jones et al 1995; Okano et al 1997; Wogen et al
2003). In principle, the ideal inception cohort consists of
recently diagnosed patients who are new to therapy, and
given that 12 months without therapy is a sufficient period
for identification of these, it appears that only half these
studies chose satisfactory inception cohorts.
Follow-up
To determine adherence, it is necessary that all prescriptions
received during the period of observation are recorded in
the database. This requires that patients receive all their
prescriptions under the scheme and that all claims are
properly recorded. Many studies required continuous
eligibility, excluding patients who died, moved away, or
otherwise became ineligible for the particular scheme. For
instance, three-quarters of initially identified patients from
the US Department of Defense cohort (Okano et al 1997)
were excluded because there were insufficient follow-up
data. However, these patients could be included if censoring
techniques had been used, thus allowing patients who are
observed for varying lengths of time from the date of
inception to be included in the study cohort (Caro, Salas, et
al 1999; Caro, Speckman, et al 1999; Bourgalt et al 2001).
Other variables
Many studies excluded patients on the basis of age; age
groups selected ranged from a relatively young cohort aged
20–49 years (Okano et al 1997) to elderly patients aged
65–99 years (Monane et al 1997).
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As all the factors listed above that were used to select
the study cohorts – particular antihypertensive, co-
prescriptions, number of drugs, duration of use, and age –
may be associated with adherence to antihypertensive
therapy (WHO 2003), it is necessary to interpret the results
of a particular study in terms of patient selection.
Outcome definitions
Table 2 gives a summary of outcome definitions and rates
estimated for each study. There was no consistent agreement
either in the terms used for outcomes or in their definitions.
Outcomes were measured as a dichotomous variable (eg,
compliant versus noncompliant) or as a continuous variable
(eg, proportion of days covered expressed as a percentage).
Outcomes might be measured at one point in time, at several
selected time points, or continuously.
Persistence
One type of outcome measure included variations on the
idea of still taking therapy after a period of time (for instance,
1 year). In some cases this type of measure focused on use
of the initial therapy, sometimes on use of the initial class,
and sometimes on use of any antihypertensive therapy. The
term usually used for this type of outcome was “persistent”,
although “continuation” was also used.
In two studies patients were defined as persistent if they
refilled their initial prescriptions on or within 3 months of
the 1-year anniversary of the starting date (Bloom 1998;
Conlin et al 2001); similarly “continuous treatment” required
a duration of over 273 days during a year of observation
(Degli Esposti L et al 2002). Elsewhere patients were
considered persistent if their final prescription covered the
period until the end of observation (Caro, Salas, et al 1999;
Caro, Speckman, et al 1999). Yet another definition of
persistence required that the patient did not miss any three
scheduled monthly refills during the course of a year (Dezii
2000).
Compliance
The term “compliance” was usually used for outcome
measures based on the proportion of days covered (PDC);
that is, the number of days the patient had a prescription
available divided by the time observed. As in the approach
described above, this might include the initial therapy only,
the initial class, or any antihypertensive, depending on the
study. In some studies patients were defined to be compliant
if their PDC was greater than 80%, while in other studies
compliance was treated as a continuous measure. The terms
“adherence” and “continuous use” were also used for this
type of measure. The term “persistent” was also used for
patients collecting a certain proportion of prescriptions
during the time observed. The use of the same terms in
different approaches highlights the inconsistencies in the
definitions of terms used in the literature.
Several studies considered patients to be compliant if
the prescriptions they received covered over 80% of the
duration of observation (Monane et al 1997; Okano et al
1997; Rizzo and Simons 1997). It has been observed that
patients receiving at least 80% of their medication are more
likely to achieve blood pressure control in both active
treatment and placebo groups (Black et al 1987). But this
does not make allowance for differences between
antihypertensive drugs or differences in patients’ responses
to therapy. Some studies used the percentage of days with
drugs available as a continuous outcome variable (Rizzo
and Simons 1997; Taylor and Shoheiber 2003; Wogen et al
2003).
Discontinuation
Discontinuation was generally defined as a gap in treatment
exceeding some specified time ranging from 30 to 90 days.
There were no attempts to validate the choice of duration of
the period without therapy. Suarez et al (2000), in their study
of the UKGPRD, found that 4 months was an insufficient
period for identification of new users of antihypertensive
therapies; that is, they found that there were a large number
of patients who, although failing to collect their prescriptions
for 4 months, returned to some form of antihypertensive
therapy. If this finding holds true for other populations, it
appears that many discontinuations may be more properly
regarded as breaks in therapy. It is important to define
discontinuation in the context of the population studied. It
is also important to follow patients throughout the period
of observation, rather than regarding such gaps in therapy
as final.
Duration of prescription availability was calculated as
time from the initial prescription until the date of discon-
tinuation. Several studies classified patients as continuers,
discontinuers, or switchers and calculated rates for each
outcome (Jones et al 1995; Dezii 2000; Bourgalt et al 2001;
Degli Esposti E et al 2002; Degli Esposti L et al 2002).
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Table 2 Outcome definitions and rates
Reference Outcomes Continuing rates Switching rates
Jones et al Continuation = still taking initial therapy (class); 6 mo (calculated monthly); 6 mo: diuretic 49%, BB 43%, CCB 52%,
(1995) not continuing if gap > 60 days diuretic 41%, BB 49%, CCB 41%, ACE 48%
Switch = stop initial therapy and prescribed ACE 45%
AHT from different class
Monane et al Compliant = PDC > 80% any AHT Calculated at 1 y; 20% patients
(1997) Switches included as compliant compliant
Rizzo and Compliance = PDC averaged over all AHT classes Calculated at 1 y: overall estimates;
Simons (1997) Switches included as compliant diuretic 5%, BB 29%, CCB 35%,
ACE 35%
Okano et al Continuous use = PDC > 80% on any AHT At 1 y: continuous use any AHT: 1 y switches/additions of therapy;
(1997) Switches included as continuous use; ACE 55.5%, CCB 49.4%; initial ACE 20.1%, CCB 22.8%
tabulated for continuous users at 1 y therapy only (including dose changes)
ACE 35.4%, CCB 26.6%
Bloom (1998) Persistent = refill initial prescription at 12 (+ 3) mo Calculated at 1 y; diuretic 38%, 1 y; diuretic 6%, BB 7%, CCB 9%,
Switch is change of AHT class BB 43%, CCB 50%, ACE 58%, ACE 9%, AT2 7%
AT2 64%
Caro, Salas, Persistent (+ cumulative rates) = last prescribed 1 y; established 97%, new 78%
et al (1999) AHT covers period until end of observation,
allowing for previous accumulation; switches
included as persistent
Caro, Persistent (+ cumulative rates) = last prescribed 6 mo; diuretic 80%, BB 85%, CCB 86%,
Speckman, AHT covers period until end of observation, ACE 89%
et al (1999) allowing for previous accumulation; switches
included as persistent
Benson et al Duration = date last prescription + days covered Median duration: 90 days all drugs
(2000) by this – start date. Discontinued if initial AHT except HCTZ comb. 80 days.
not available > 30 days and no AHT within Note: only patients who discontinued
90 days of end AHTs included
Dezii (2000) Persistent (monthly) = initial AHT without At 1 y (calculated monthly);
missing > 3 prescriptions in year observed lisinopril /HCTZ 1 tab 68.7%,
Not persistent if failing to renew 3 prescriptions 2 tabs 57.8%
during year
Bourgalt et al Time to first modification = any change of initial 1 y no modification 33.8%; 5 y no 1st modification: addition 20.1%, switch 
(2001) therapy (drug titration allowed) modification 11.5%; BB 7.9%, 14.3%, interruption (gap > 90 days)
Switch = change therapy (class) and stop initial CCB 9.3%, ACE 13.1%, 31.5%, discontinue 22.6%
AHT; maximum gap 90 days combination 22.3%
Conlin et al Persistent = refill initial AHT at 12, 24, 36, At 1 y (calculated yearly); 1 y; diuretic 18.8%, BB 6.4%, CCB 9.8%,
(2001) 48 (+ 3) mo diuretic 20.8%, BB 45.6%, ACE 9.6%, AT2 8.0%
Switch = no initial AHT and change AHT class in CCB 54.1%, ACE 60.7%, AT2 67.4%
follow-up intervals
Ren et al (2002) Compliance rates = PDC any AHT excluding At 2 y; compliant 72.8%
last prescription
Compliant = PDC > 80% not including last
prescription
Degli Esposti E Persistence = duration first–last prescription any 3 y; 57.9% continue Restart 7.6%; ≥ 2 AHTs 1st and 3rd year
et al (2002) AHT; continuing if > 1 AHT each year and < 2 AHTs 2nd year
Switches include continuers
Marentette Persistence = prescription from initial class only Calculated at days 180, 360, 540, 180 days; mixed 79.7%
et al (2002) within previous 90 days at 4 time points 720; 360 days overall 63.8%; 180 days
Switches included in “mixed” class diuretic 52.0%, BB 67.2%, CCB 69.8%,
ACE 75.1%, AT2 87.8%
continued overleaf
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Change of therapy
Some studies considered switches or changes of regimen
as continuation of therapy (Monane et al 1997; Okano et al
1997; Rizzo and Simons 1997; Caro, Salas, et al 1999; Caro,
Speckman, et al 1999; Degli Esposti E et al 2002; Ren et al
2002; Wang et al 2002), whereas others classified this as
discontinuation of the initial therapy. The studies that
focused on continuation with the initial therapy mostly
ignored additional drugs (Jones et all 1995; Bloom 1998;
Benson et al 2000; Dezii 2000; Conlin et al 2001; Degli
Esposti L et al 2002; Wogen et al 2003) but in some instances
classified these as modification of therapy (Bourgalt et al
2001; Hasford et al 2002). To get a clearer picture of
prescription patterns, information on prescriptions of
antihypertensives other than the therapy initially prescribed
should be included in the analysis. This information should
include time and type of therapy. Analysis of such
information requires the use of an appropriate statistical
model.
The broad definition of adherence as proposed by the
WHO allows flexibility in the definition of quantitative
measures. This is useful, as it encompasses the many aspects
of adherence. But because there is no standard quantitative
definition, care must be taken in the interpretation of studies
that attempt quantitative assessment of adherence. A further
complication is the use of the same terms to mean different
things. Quantitative studies of adherence should be
interpreted in the light of the definitions they use and their
justification of these definitions.
Outcome rates and analyses
Table 3 gives details of the results on adherence rates
according to individual study definitions and includes
associations with other variables.
Models used
The earlier studies limited their measurement of outcomes
to a single point in time and in some cases no modeling was
attempted, the focus being on the level of adherence as
defined by the particular study at this point in time. Several
studies examined the significance of chosen covariates
using logistic regression (Hosmer and Lemeshow 2000)
typically to predict good adherence or persistence at 1 year
(Monane et al 1997; Bloom 1998; Caro, Salas, et al 1999;
Caro, Speckman, et al 1999; Wogen et al 2003). Good
compliance at 1 year was predicted using age, sex, type of
Table 2 continued
Reference Outcomes Continuing rates Switching rates
Wang et al Compliance = PDC any AHT tertiles (50%, 80%) Calculated at 1 y; PDC > 80% in
(2002) Switches included as compliant 29% of patients
Hasford et al Persistence = initially prescribed monotherapy; 1 y overall 46.8%; diuretic 34.4%, 1 y; add 23.8%, change 12.9%
(2002) discontinue = gap > 30 days BB 49.7%, CCB 43.6%, ACE 42.0%,
Switch = any change from initial monotherapy other AT2 51.3%, irbesartan 60.8%
Duration on initially prescribed monotherapy
(until switch/discontinue/end observation)
Degli Esposti L Persistence = continue with initial therapy after 1 y overall 26.9%; diuretic 23.1%, 1 y overall 8.2%; diuretic 7.1%, BB 6.7%,
et al (2002) 9 mo (continuers/switchers) BB 30.9%, CCB 23.7%, ACE 30.7%, CCB 7.6%, ACE 9.4%, AT2 24.6%
Duration any AHT time covered first–last AT2 33.4%
prescription
Wogen et al Persistence = remain on initial AHT no 1 y overall 54%; valsartan 63%,
(2003) gaps > 60 days amlodipine 53%, lisinopril 50%
Switches not analyzed. Duration = last prescription
date – first prescription date (initial AHT)
Taylor and Adherence = PDC excluding last prescription Calculated at last prescription
Shoheiber 2 tablets: time is first prescription second observed: combination 80.8%,
(2003) drug – last prescription last drug ACE + CCB 73.2%
(ie, sequential/combined)
Degli Esposti Persistence = continue with initial therapy after 1 y overall 30.9%; diuretic 25.9%, 1 y overall 8.8%; diuretic 7.3%, BB 6.5%,
et al (2004) 9 mo (continuers/switchers) BB 36.9%, CCB 26.9%, ACE 32.2%, CCB 8.6%, ACE 10.6%, AT2 13.2%
Duration any AHT time covered first–last AT2 41.7%
prescription
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BB, β-blocker; CCB, calcium channel blocker; AT2, angiotensin-II antagonist; AHT, antihypertensive;
HCTZ, hydrochlorothiazide; PDC, proportion of days covered; mo, month; y, year.
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Table 3 Summary of results from the studies
Survival Other
Reference analysis analyses Control Significant Nonsignificant Comments
Jones et al ANOVA Continuers: nr of GP visits inc, nr of AHT Frequency of
(1995) Compare continuers prescriptions dec (significance levels not continuation
vs switch/discontinue given) decreased with
duration
Monane et al Logistic for good Age (3 groups), sex, OR (95% CI) Thiazide dose Analysis repeated for
(1997) compliance at 1 y race, start year Thiazide 1.0, BB 1.4 (1.2, 1.7), patients with > 1
CCB 1.7 (1.5, 2.1), ACE 1.9 (1.6, 2.1), prescription and
CHF/CAD 1.2, > 8 GP visits 2.2, > 8 other with CHF/CAD –
medicines 0.8, redeem at > 1 pharmacy 0.4 same
Rizzo and OLS for 1 y Duration dec, BB duration inc, CCB Sex, asthma, Significance level 0.01
Simons (1997) compliance duration inc, ACE duration inc, age inc, COPD,diabetes, Also OLS regression
white inc, medical resources inc, CHF inc renal failure, for costs
angina, LVH,
AMI, PAD, TIA
Okano et al None Tables for rates of
(1997) compliance only
Bloom (1998) Logistic for OR (95% CI) Sex – OR is 1.08
persistence at 12 mo Thiazide 0.36 (0.30, 0.43), BB 0.56 (1.02–1.15); clinically
(0.47, 0.68), CCB 0.62 (0.51, 0.74), ACE 0.81 uncertain and don’t
(0.68, 0.97), AT2 1.00, age > 65 y 1.00, specify whether male
age 40–65 y 0.79, age < 40 y 0.32; vs female or vice versa
> 1 dose/day 1.40
Caro, Salas, Kaplan-Meier, Logistic for 12 mo OR Log-rank test for new
et al (1999) log-rank test persistence Age > 60 y 1.11, female 1.16, established vs established HT
HT 10.73, > 3 other medicines 1.29, significant p < 0.001
> 5 GP visits 1.59, hospital admission 0.75
Caro, Kaplan-Meier, Logistic for 12 mo Age, sex, GP visits, OR (95% CI) Log-rank test for drug
Speckman, log-rank test persistence other medicines, Diuretic 1.00, BB 1.25 (1.12, 1.39), CCB 1.51 class significant
et al (1999) for drug class hospitalization (1.36, 1.69), ACE 1.92 (1.76, 2.09) p < 0.001
Benson et al ANCOVA for median Men significantly longer therapy overall and Drug type Duration difference
(2000) duration between for atenolol, quinapril, HCTZ + triamterene men vs women may
drugs not be clinically
significant
Dezii (2000) % persistent Test single tablet vs 2 separate drugs at 6
plotted vs and 12 mo; test not stated but significant
month (p < 0.05)
Bourgalt et al Cox PH for Poisson regression Age inc, female inc, BB vs others dec, Hazard ratios not
(2001) time to first for modification rates combination vs others inc given in paper
modification
of initial
therapy
Conlin et al % persistent OLS regression for Predicted difference in persistence rates vs Log transform
(2001) each 6 mo difference in AT2s: Thiazide –68.8%, BB –34.5%, persistence rate
plotted vs persistence rate over CCB –20.8%, ACE –10.1%; p < 0.001
time time (12–48 mo)
Ren et al OLS regression for Predictors of compliance: age inc, nr of Race, education
(2002) compliance (over 2 y) medications inc, input to treatment > 13 y, doctor’s sex,
decisions inc, doctor age dec, speciality practice size
care resident vs primary care, other
healthcare provider vs doctor
Degli Esposti E Cox PH for Hazard ratios for discontinuation: Comorbidity, Patient age then drug
et al (2002) duration age (1 y) 0.976 (0.974, 0.978), female 0.894 previous class have most
first–last (0.832, 0.961), diuretic 2.624 (1.992, 3.457), hospitalization, influence on
prescription BB 1.869 (1.414, 2.472), CCB 2.073 district, practice persistence
(1.574, 2.731), ACE 1.577 (1.198, 2.076), size
AT2 1.00, GP age 1.006 (1.002, 1.011),
GP female 0.911 (0.836, 0.992)
Marentette Persistence Repeated measures Age, female, drug class – all pairwise Increasing age
et al (2002) plotted vs ANCOVA for comparisons significant except CCB and BB, increases persistence,
time for drug relationship between female · drug class, age · drug class mainly because
classes drug class and younger patients
persistence especially taking BB,
CCB, diuretics
continued overleaf
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Table 3 continued
Survival Other
Reference analysis analyses Control Significant Nonsignificant Comments
Wang et al Ordinal logistic Age, sex, race, OR (95% CI) Health beliefs,
(2002) regression for PDC education, Depression (1 point on 15-point scale) knowledge of HT,
tertiles employment, treat 0.93 (0.87, 0.99), social support,
site, thiazide use, external locus of control (6-point scale) satisfaction, alcohol
comorbidities 1.15 (0.99, 1.33) use, smoking, socially
desirable responding,
depression diagnosis
Hasford et al Kaplan-Meier Hazard ratios not given
(2002) for differences Patients on irbesartan significantly more
in drug classes likely to persist with initial therapy than all
Cox PH for others
time on initial
monotherapy
Degli Esposti L Cox PH for ANOVA to compare Hazard ratios for discontinuation: Sex, asthma drugs
et al (2002) time to patient ages in age (+1 y) 0.982 (0.981, 0.983), AT2 1.00,
discontinuing continuers, switchers, diuretics 2.442 (2.044, 2.917), BB 1.525
initial AHT discontinuers and in (1.272, 1. 829), CCB 1.913 (1.602, 2.284),
(additions drug classes ACE 1.695 (1.419, 2.025), heart disease 1.531
included) (1.238, 1.894), diabetes 1.509 (1.242, 1.834),
PH assumption previous CVD hospitalization 1.524
tested (1.394, 1.667), ≥ 2 comorbidities 1.571
(1.334, 1.851)
Wogen et al Cox PH for OLS regression for Hazard ratios for discontinuation: p < 0.0001
(2003) time to compliance (PDC) in all cases unless stated:
discontinuation age 0.933, male 0.954, valsartan 1.00,
of any AHT amlodipine 1.333, lisinopril 1.446,
diuretics 1.103, diuretic combination 1.544,
BB 1.131, nitrates 1.137, LLDs 0.743,
chronic disease score 1.013, digitalis 1.049
(p = 0.0012), antiplatelets 1.032 (p = 0.018)
Taylor and No modeling; Stratified for age Amlodipine/benazepril vs ACE + CCB Sequential
Shoheiber chi-square and group; morbidity prescriptions of ACE,
(2003) t-tests score (Charlson CCB considered for
index) MPR
Degli Esposti Cox PH for OLS regression for Hazard ratios for discontinuation: Sex, asthma drugs
et al (2004) time to costs age (+1 y) 0.978, diuretic 1.853,
discontinuing CCB 1.663, ACE 1.386, AT2 1.00,
initial AHT heart disease 1.666, diabetes 1.394,
previous CVD hospitalization 1.507,
≥ 2 comorbidities 1.630
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BB, β-blocker; CCB, calcium channel blocker; AT2, angiotensin-II antagonist; AHT, antihypertensive;
LLD, lipid-lowering drug; CVD, cardiovascular disease; HF/CHF, heart failure; CAD, coronary artery disease; HT, hypertension; COPD, chronic obstructive pulmonary
disease; LVH, left ventricular hypertrophy; AMI, acute myocardial infarction; PAD, peripheral arterial disease; TIA, transient ischemic attack; PDC, proportion of days
covered; MPR, medication possession ratio; OLS, ordinary least squares; PH, proportional hazards; ANCOVA, analysis of covariance; ANOVA, analysis of variance; OR,
odds ratio; CI, confidence interval; dec, decrease; inc, increase; mo, month; y, year.
antihypertensive therapy, and other variables (Monane et al
1997). Ordinary least squares regression was used to model
compliance as a continuous variable, usually calculated as
the medication possession ratio, in terms of covariates (Rizzo
and Simons 1997; Conlin et al 2001; Ren et al 2002). Simple
survival analysis methods, notably the construction of
Kaplan-Meier curves showing the proportion of patients still
taking their medications plotted against time, attempt to
illustrate the time dependence of the outcome (Caro, Salas,
et al 1999; Caro, Speckman, et al 1999; Dezii 2000; Conlin
et al 2001; Hasford et al 2002). Survival analysis in this
context is based on the probability that individuals still
receive their prescriptions at various points in time. One of
the earliest studies to use Cox proportional hazards modeling
(Hosmer and Lemeshow 1999), a regression method for
modeling survival data, to assess duration of therapy in terms
of covariates was based on Canadian data (Bourgalt et al
2001), and several subsequent studies used the same type
of analysis (Degli Esposti E et al 2002; Degli Esposti L et al
2002; Gregoire et al 2002; Hasford et al 2002; Wogen et al
2003). These did not all make full use of the capability of
this type of modeling to deal with censored observations
(observations that do not have complete follow-up data). In
this context, there are two problems with Cox models that
were not adequately addressed. One is that it is assumed
there are no time-dependent covariates. Another is that where
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persistent (Caro, Speckman, et al 1999; Conlin et al 2001),
two find men more persistent (Benson et al 2000; Wogen et
al 2003), and some find no difference in outcome rates
between men and women (Rizzo and Simons 1997; Degli
Esposti L et al 2002). Some find no relationship with age,
while others find older patients more likely to adhere with
their antihypertensive therapies (Rizzo and Simons 1997;
Bloom 1998; Caro, Speckman, et al 1999; Conlin et al 2001;
Degli Esposti L et al 2002; Ren et al 2002; Wogen et al
2003). Age is often dichotomized, a typical cut-off point
being 65 years, though in some studies it is included as a
linear variable (Degli Esposti L et al 2002; Wogen et al
2003). However, the nature of the association is not further
explored. In any case, the relationships with these factors
are relatively weak and should be interpreted with caution.
Other patient factors
Two of the studies used patient interviews as well as
prescription data. One study found an association between
increasing depression symptom severity and compliance
with antihypertensive therapy; however, it failed to find any
association between health beliefs, knowledge of hyper-
tension, social support, or satisfaction with care and
compliance (Wang et al 2002). The other found that patients
who were involved in treatment decisions were more likely
to be compliant (r = 0.64) (Ren et al 2002).
Healthcare system factors
Several studies investigated aspects of the relationship
between patients and the healthcare system. The number of
visits to the doctor was found to have a positive association
with the adherence measure (Jones et al 1995; Monane et al
1997; Caro, Salas, et al 1999). Two studies found that
younger doctors tended to have more adherent patients
(Degli Esposti E et al 2002; Ren et al 2002). One study
found that patients treated by nurses or physicians’ assistants
were more likely to be compliant than patients treated by
physicians (Ren et al 2002). Patients who had previously
been hospitalized were found more likely to be persistent
with antihypertensives in large Canadian and Italian studies
(hazard ratio = 1.52; p < 0.05) (Caro, Salas, et al 1999; Degli
Esposti L et al 2002), but an investigation using a smaller
sample from the same Italian population found previous
hospitalization to have no association with persistence (Degli
Esposti E et al 2002). One study found that patients who
did not collect all their antihypertensive prescriptions from
the same pharmacy were less likely to be compliant (odds
the data are available on a monthly basis, as is often the
case with prescription claims, the model must be adapted to
deal with the fact that durations of prescription availability
are discrete rather than continuous.
Adherence rates
Tables 2 and 3 summarize the findings from individual
studies. The 1-year adherence rates are shown (where
available) for selected studies in Table 2. These adherence
rates are based on the outcome measures as defined in
individual studies. From one database, they range from
33.8% of patients having made no modification of treatment
at 1 year (Bourgalt et al 2001) to 78% of new users of
antihypertensives persisting with treatment at 1 year (Caro,
Salas, et al 1999). Interestingly, these results were based on
patient populations drawn from the same database,
Saskatchewan Health, which emphasizes the importance of
patient selection and outcome definitions. Bourgalt and
colleagues included all patients who were new to
antihypertensive therapy and observed for at least 1 month
after the initial prescription (so that patients who left the
scheme were treated as censored and included in the
analysis) and the outcome was any modification in treatment,
which included treatment gaps, discontinuations, and
addition or substitution of drugs. Caro, Salas, and colleagues
included patients who were new users of antihypertensives
and were observed for at least 1 year from the inception
date (ie, censored patients were excluded). These patients
were considered persistent if their final prescription, which
could be for any antihypertensive drug, covered the period
until the end of the observation year. There are several
reasons for the discrepancies in reported results. One is the
selection bias resulting from the exclusion of patients who
left the scheme during the observation year. Another is the
definition of the adherence outcome to include prescription
of any antihypertensive drug at the end of the year (ie,
switches included; Caro, Salas, et al 1999) as opposed to
the initial monotherapy (ie, any type of modification
classified as nonadherence with the initial therapy; Bourgalt
et al 2001).
Demographic factors
Table 3 shows significant and nonsignificant factors
associated with adherence outcome measures. There are
some inconsistencies in the results, especially with regard
to the association of demographic factors such as age and
sex with outcomes. Some studies find women more
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ratio [OR] = 0.4; p < 0.05, for visiting > 1 vs single pharmacy)
(Monane et al 1997).
Therapeutic regimen factors
Complexity of the therapeutic regimen is known to have a
negative effect on adherence. Two studies found that patients
taking a medication as a combination tablet were more
persistent with that treatment than patients who took two
separate tablets (Dezii 2000; Taylor and Shoheiber 2003),
while another found that taking more than one dose per day
had a negative effect on persistence (OR = 1.40; p < 0.05)
(Bloom 1998).
Some authors used information on other prescriptions
for therapies other than the antihypertensives of interest
either to select patients or to include as covariates in models
for adherence. There was conflicting evidence on the
influence of co-prescriptions on adherence. Prescription of
a large number of other medications was found to have a
negative (large defined as more than eight medications) and
also a positive (large defined as three medications) effect
on adherence outcome rates (Monane et al 1997; Caro, Salas,
et al 1999; Ren et al 2002). Similarly, a high chronic disease
score (Wogen et al 2003) or evidence of two or more
comorbidities (Degli Esposti L et al 2002) reduced the risk
of discontinuation. Specifically, patients with evidence of
heart disease and diabetes were found to be more persistent
(Degli Esposti L et al 2002), as were patients with heart
failure (Rizzo and Simons 1997).
Several studies set out to examine whether there were
differences in adherence rates between drug classes.
Although one study found no difference (Benson et al 2000),
most concluded that patients were least likely to adhere with
diuretic therapy, followed in various order by β-blockers,
calcium channel blockers, ACE inhibitors, and angiotensin-
II antagonists (Rizzo and Simons 1997; Bloom 1998; Caro,
Speckman, et al 1999; Conlin et al 2001; Degli Esposti E et
al 2002; Degli Esposti L et al 2002; Hasford et al 2002;
Wogen et al 2003). However, this may be due to patient
selection rather than an effect of the particular therapies.
Discussion
This review has shown that there is a wide variability in the
rates of nonadherence with antihypertensive therapies, but
most of this variability is due to differences in methods and
definitions used in the various studies. Owing to lack of
comparability, no meta-analysis, combining results from the
various studies, was attempted.
Prescription databases give no information on the pattern
of drug ingestion on a daily basis. They provide information
on drug supply; patients are unlikely to continue collecting
prescriptions if they have stopped taking their medicines.
In some cases, for instance in health insurance schemes,
patients may collect their prescriptions and hoard their
medicines, but we have no evidence to suggest this.
Prescription databases provide information on what
prescriptions were collected but not what was actually
prescribed by the doctor or consumed by the patient, so
that for the assessment of adherence the assumption is made
that the medicine type and quantity received is exactly what
was prescribed. In particular, it may not be valid to assume
the daily dose prescribed. When attempting to quantify
adherence, the most appropriate use of these data is to
ascertain discontinuations and changes of therapy. To do
this, it is necessary that all prescriptions collected by the
patient during the time of observation are included in the
database. Analysis methods that allow for censored
observations can be used to include information on patients
who leave the scheme before the end of the observation
period. There is less justification for using prescription refill
data to estimate percentage levels of patient adherence. As
it is typically estimated over a year, a percentage estimate
of adherence takes no account of the longitudinal structure
of the data. Thus an estimate of the adherence of a patient
who fails to collect a prescription in the third, fifth, and
ninth months will be the same as for one who collects
prescriptions continuously for 9 months and then stops.
Previous reviews of the assessment of adherence using
prescription databases have made some important
observations on the scope and limitations of this approach,
which have often not been adequately addressed in
subsequent studies (Steiner and Prochazka 1997; Payne and
Esmonde-White 2000). Since these reviews were published
there have been advances in the application of modeling
techniques, notably the use of more sophisticated survival
techniques such as Cox proportional hazards modeling.
Methods of analysis that choose a single point in time
for the outcome and require that all patients must be observed
until this point may introduce selection bias and do not allow
for any modeling of patterns of prescriptions received over
time. Survival analysis methods, such as the Cox
proportional hazards model, allow the inclusion of patients
who are not observed over the entire time period and can be
used to analyze continuous prescription refills over time.
But as noted above, the Cox model assumes proportionality
of baseline hazards (ie, the baseline risk is proportional to
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time) and is perhaps not the best way of dealing with time-
dependent covariates. It also assumes continuous time, so
that where prescriptions are dispensed monthly (ie, on a
discrete-time basis), there may be problems with multiple
ties in the survival times. A model allowing for discrete
survival times may be more appropriate.
Many of the studies on this topic seem to rework the
same ground without providing new insight and perhaps
perpetuate the same flaws in design, analysis, and
interpretation. The contribution they make is to reinforce
the point that nonadherence rates are very high. Rather than
additional large cohort studies, attention should focus on
the appropriate design and methodologies of these studies.
The analyses used in previous studies are mostly
rudimentary, and conclusions drawn may be unjustified. One
particular problem is that the studies are observational in
nature and there are inherent biases associated with this;
for example, individual characteristics that may affect drug
adherence may also have an association with the type of
drug prescribed.
This is not considered in most studies. For instance, the
better compliance rates for angiotensin-II antagonists are
attributed solely to characteristics of the drug (particularly
the placebo-like adverse effect profile). But the relationship
between adverse effects and discontinuation is not fully
understood and appears to depend upon context. According
to a meta-analysis of clinical trials, approximately 3.1% of
patients treated with angiotensin-II antagonists or diuretics
will discontinue therapy because of adverse effects (Ross
et al 2001); however, in the observational studies examined
here, 33%–67% of patients starting an angiotensin-II
antagonist and 62%–79% of patients starting a diuretic had
discontinued their initial treatment by the end of the first
year. A Canadian study that followed 682 patients who were
newly prescribed antihypertensives found that 62% reported
adverse effects and 50% of these discontinued their initial
therapy, in comparison with a 31% discontinuation rate
among patients who did not report adverse effects (Gregoire
et al 2002). A Japanese questionnaire-based study found
49% of patients with well controlled blood pressure
reporting adverse effects with their antihypertensive
medicines and a statistically significant relationship between
the number of reported adverse effects and nonadherence
(Toyoshima et al 1997). However, it has been observed
elsewhere that patients who discontinue are less likely to
respond to questionnaires (Suarez et al 2000), so that the
results of this study should be interpreted with caution.
Certainly it is known that polypharmacy increases the risk
of adverse effects due to drug interactions. It has been
observed that patients who are more ill, and therefore are
prescribed more drugs, are also more likely to adhere with
their treatment. There are many complex interacting factors
that affect patient adherence; quantification of these remains
a problem.
The results reported in the observational studies tabulated
here should be interpreted carefully in terms of context,
patient and regimen selection, and definitions of adherence.
There is a need for more sophisticated statistical modeling
appropriate to the discrete-time longitudinal structure of the
data. Given that prescription refills are effectively repeated
measures on individual patients, random effects models,
incorporating patient-specific variability, may give further
insights into the patterns of antihypertensive use at the
individual level (Goldstein 2003).
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